EmbeddingGemma 2: an open, lightweight multimodal embedding model
deepmind.google·6d ago
AI Engineering
Hacker News·Aug 26·5 min read
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
TL;DR
The FDA has approved Rasonque (daraxonrasib), a groundbreaking RAS inhibitor for metastatic pancreatic adenocarcinoma, significantly improving patient survival rates. This approval offers a new treatment option for patients who have limited alternatives.
✦ Why It Matters
Consider discussing Rasonque with healthcare providers if you or someone you know is affected by pancreatic cancer.
Key Takeaways
- Rasonque is a new treatment option for advanced pancreatic cancer.
- It targets the RAS protein, crucial for tumor growth.
- Clinical trials showed improved survival rates compared to standard chemotherapy.
- FDA expedited the approval process due to high unmet medical need.
Full Summary
Rasonque, a daily oral tablet, targets RAS proteins that drive tumor growth in pancreatic adenocarcinoma, the most common form of pancreatic cancer. The FDA's approval comes after a clinical trial involving 500 adults, where Rasonque improved median overall survival to 13.2 months compared to 6.7 months with standard chemotherapy.
This approval is notable as it was granted 6.5 months ahead of the user fee deadline, reflecting the FDA's commitment to expedite cancer treatment approvals. Rasonque is specifically for adults with metastatic pancreatic adenocarcinoma who have undergone at least one prior systemic therapy.
The drug received Breakthrough Therapy and Orphan Drug designations, highlighting its potential to address significant unmet medical needs. Common side effects include rash, diarrhea, and nausea, among others.